93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

E. Chen, Leonard W. Seymour, M. Maclean et al.|European Journal of Cancer Supplements|2006

Cited by 2